key: cord-0890670-oc1ift2z
authors: Sahu, Kamal Kant; Mishra, Ajay Kumar; Mishra, Kundan
title: Methemoglobinemia in COVID-19
date: 2021-05-10
journal: Am J Med Sci
DOI: 10.1016/j.amjms.2021.04.020
sha: 5995d968c0284e7bbd0a7f95d5fda582ebd32395
doc_id: 890670
cord_uid: oc1ift2z

nan

The COVID-19 pandemic has proven to be devastating for all the countries. 1 The treatment has been mostly limited to symptomatic and supportive care. Various drugs have been repurposed and tried for their potential role in treatment of COVID-19. 2 At the same time, management of the adverse reactions secondary to these new and experimental drugs has been a matter of concern. In this letter, we discuss the literature available on methemoglobinemia in patients suffering from COVID-19.

In total, we found eight cases of methemoglobinemia and COVID-19 reported till October 30, 2020 (Table 1) . Largest case series has been reported by Naymagon et al consisting of 3 patient data. 3 Table 1 shows that all patients were male, mostly middle aged. Maximum methemoglobin level of 30% or more was reported in 2 patients. 3, 4 Except one, all of the other seven patients did receive hydroxychloroquine (HCQ) as a part of treatment strategy for COVID-19 patients. 5 Almost all patients were critically ill and required intensive level of care.

Intravascular hemolysis in addition to methemoglobinemia was noted in four patients. [4] [5] [6] [7] Except the case reported by Palmer et al, all other cases required treatment with one or more antioxidants namely methylene blue, ascorbic acid, vitamin B12 and red blood cell exchange. [3] [4] [5] [6] [7] [8] Outcome of the patients of this study group was variable, four patients were successfully discharged after recovery, three patients were still admitted while case reporting, and one patient succumbed to his illness.

Methemoglobin is formed when iron in hemoglobin gets oxidized from ferrous [Fe2+] state to the ferric [Fe3+] state. Drugs including HCQ have the potential to initiate this reaction by reducing free O2 to the free radical O2-. This in turn oxidizes hemoglobin to methemoglobin.

Various drugs have variable potency to accelerate this oxidation reaction from 100 to 1,000 times. Similarly, the body tries to keep the methemoglobin level in the blood to a minimum via cytochrome-b5 reductase mediated reduction process which requires NADH. In the event of excessive methemoglobin production, the body's normal homeostatic mechanism is not able to nullify the overproduction of methemoglobin which ultimately leads to methemoglobinemia.

The study shows that management of COVID-19 can get complicated due to unforeseen reasons, and hence, high vigilance is of the utmost importance. Drugs like HCQ, azithromycin, etc., could potentially lead to fatal methemoglobinemia and/or intra vascular hemolysis leading to higher mortality. Other factors like congenital disorders (e.g., thalassemia, sickle cell disease, and hereditary spherocytosis) can potentially worsen the anemia due to their various pathophysiological mechanisms. [9] [10] [11] [12] In cases with co-existent G6PD deficiency, methylene blue use could be detrimental as it worsens the hemolysis. 4 In such scenarios, use of ascorbic acid and vitamin B 12 has been shown to be beneficial. 13, 14 To conclude, though use of HCQ has gone down significantly especially in developed countries, it is still a prevalent drug in use in developing nations and knowledge about the associated side effects could be lifesaving. 

Managing blood disorders during the Covid-19 pandemic: current pharmacological insights

Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine

The emergence of methemoglobinemia amidst the COVID-19 pandemic

Rapidly rising methemoglobinemia in a patient with severe COVID-19 treated successfully with red cell exchange transfusion

Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection

Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine

Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report

Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury

A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine

COVID-19 infection and treatment with

COVID-19 and hereditary spherocytosis: A recipe for hemolysis. Pediatr Blood Cancer

Closing the saturation gap: a ten-year retrospective experience with methemoglobinemia

Methemoglobinemia in a Case of Paint Thinner Intoxication, Treated Successfully with Vitamin C